AstraZeneca said it will begin selling a China-made cancer drug directly in the United States after criticism that it was too slow to bring the treatment to American patients. Some US patients had previously traveled to Shanghai to obtain the medicine, which American regulators had already approved. The move highlights growing frustration over pricing and availability gaps between the world's two largest pharmaceutical markets.